Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
With a market cap of 126.66B, Vertex Pharmaceuticals(VRTX) trades at $499.74. The stock has a price-to-earnings ratio of 29.00.
On 2026-10-16, Vertex Pharmaceuticals(VRTX) stock traded between a low of $497.49 and a high of $512.34. Shares are currently priced at $499.74, which is +0.5% above the low and -2.5% below the high.
Vertex Pharmaceuticals(VRTX) shares are trading with a volume of 1.4M, against a daily average of 1.29M.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $403.16 at its lowest and $560.25 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $403.16 at its lowest and $560.25 at its peak.
VRTX News
Vertex Pharmaceuticals (VRTX Quick QuoteVRTX - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want t...
In 2012, Vertex Pharmaceuticals (VRTX +2.86%) earned approval for the first medicine that targeted the underlying causes of cystic fibrosis (CF), a rare disease...
...
Analyst ratings
77%
of 35 ratingsMore VRTX News
Vertex Pharmaceuticals reported interim data from an open label extension study of ALYFTREK in 2 to 5 year old children with cystic fibrosis, showing recovery o...
Can the pioneer of mRNA vaccines outpace the king of cystic fibrosis treatments? Choosing between Moderna (MRNA -5.00%) and Vertex Pharmaceuticals (VRTX -0.60%)...
BofA lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $667 from $672 and keeps a Buy rating on the shares after updating estimates ahead of t...
has delivered a powerful long term share price run, yet the key issue for anyone looking at the stock today is whether its current US$510.08 level is supported...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.